A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. - Wagner,H.J.; Bollard,C.M.; Vigouroux,S. (Cancer Gene Ther, 2004)